Selecta Biosciences (SELB) Investor Presentation - Slideshow

Company Overview - Selecta Biosciences' ImmTOR platform has broad applicability in biologics and gene therapy, with a diversified pipeline expanding to autoimmune diseases and targeted partnerships to maximize platform potential[6] - The company's precision immune tolerance platform aims to restore self-tolerance in autoimmune disease and overcome immunogenicity of gene therapies and biologics[6] - Selecta Biosciences has funding into mid-2024 to support development across pipeline programs[6, 144] ImmTOR Platform & Technology - ImmTOR combines nanoparticle technology with an FDA-approved anti-inflammatory and immunomodulatory drug to generate antigen-specific immune tolerance[9] - Preclinical data indicates a potentially profound synergy of ImmTOR and engineered Treg-selective IL-2 (ImmTOR-IL) to expand antigen-specific Tregs and improve durability of immune tolerance[6] - ImmTOR, by inhibiting the formation of neutralizing antibodies, could make redosing of gene therapies possible[58] Clinical Programs & Pipeline - SEL-212 in chronic refractory gout has dosed over 400 patients, with Phase 3 DISSOLVE I expected readout in Q4 2022[6] - SEL-302: IND for gene therapy program in methylmalonic acidemia (MMA) was submitted in Q3 2021, with Phase 1 start expected in 2H 2022[6, 88] - In a Phase 2 trial, 66% of patients treated with SEL-212 (pegadricase + ImmTOR) maintained control of serum uric acid (SUA), compared to only 15% treated with pegadricase alone[112, 115] - In a study with healthy volunteers, 100% of subjects dosed with 0.3 mg/kg ImmTOR had NAb titers ≤1:25 at Day 30[77]